Study of ACTG2 gene changes in children with intestinal blockage
Part of Digestive system clinical trials.
This study looks at how changes (mutations) in a gene called ACTG2 affect the muscles that move food through the gut in children and adults with a rare condition called pediatric intestinal pseudo-obstruction (PIPO). It may help researchers understand the condition better and find new ways to help patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 4 years old or older
- You were diagnosed with pediatric intestinal pseudo-obstruction (PIPO) before age 18
- You have at least 2 out of the standard criteria for PIPO (as defined by doctors) and carry a specific change in the ACTG2 gene (types: R178, R257, R40, or A136)
- You or your guardians agree to take part and sign a consent form
- You are part of the French Social Security system or have equivalent health coverage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if a genetic test can find causes of a rare condition where the intestines don't move normally, causing blockages. It may help people with poor esophagus muscle function.
This study looks at the gut bacteria (microbiome) of children and young adults with CIPO who have a stoma, to see if there is a link with belly pain. It may help doctors understand why some people with CIPO have pain and could lead to better treatments.
This trial tests how well a new enzyme treatment (cipaglucosidase alfa with miglustat) works and how safe it is in children and babies with infant-onset Pompe disease. It may help by improving muscle function after earlier treatment or, for some babies, starting treatment when no prior enzyme therapy has been given.
This study tracks the health of people with a confirmed ACTA2 gene change over time to better understand the disease. It may help researchers learn how to improve care for this condition.
This study looks at how the csgA gene changes over time in people with Parkinson's disease, especially if they have stomach or bowel issues. It aims to help understand how these changes might relate to symptoms.
This early-phase study tests a gene therapy meant to treat people who have IGHMBP2 gene changes. It aims to improve the way the nervous system works and to see if the treatment is safe, especially in young children.
Hear when a new PIPO trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.